PSS17 - COST PER RESPONDER ANALYSIS OF BRODALUMAB COMPARED WITH USTEKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA
Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.2517
https://www.valueinhealthjournal.com/article/S1098-3015(18)35819-4/fulltext
Section Title :
Section Order :
1872
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35819-4&doi=10.1016/j.jval.2018.09.2517